within Pharmacolibrary.Drugs.ATC.J;

model J01MA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.92,
    Cl             = 4.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.014666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Pefloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic formerly used for the treatment of various bacterial infections, including urinary and respiratory tract infections. It is not widely approved or used in many countries today due to safety concerns, particularly related to tendon damage and CNS effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Frydman, AM, et al., &amp; Gaillot, J (1986). Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. <i>The Journal of antimicrobial chemotherapy</i> 17 Suppl B 65–79. DOI:<a href=&quot;https://doi.org/10.1093/jac/17.suppl_b.65&quot;>10.1093/jac/17.suppl_b.65</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3458699/&quot;>https://pubmed.ncbi.nlm.nih.gov/3458699</a></p></li><li><p>De Lepeleire, I, et al., &amp; De Schepper, PJ (1988). Comparative oral pharmacokinetics of fleroxacin and pefloxacin. <i>The Journal of antimicrobial chemotherapy</i> 22(2) 197–202. DOI:<a href=&quot;https://doi.org/10.1093/jac/22.2.197&quot;>10.1093/jac/22.2.197</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3141343/&quot;>https://pubmed.ncbi.nlm.nih.gov/3141343</a></p></li><li><p>Malik, JK, et al., &amp; Shukla, DC (2002). Pharmacokinetics of pefloxacin in goats after intravenous or oral administration. <i>Veterinary research communications</i> 26(2) 141–149. DOI:<a href=&quot;https://doi.org/10.1023/a:1014047702196&quot;>10.1023/a:1014047702196</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11922483/&quot;>https://pubmed.ncbi.nlm.nih.gov/11922483</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01MA03;
